Song Young Shin, Oh Tae Jung, Kim Kyoung Min, Moon Jae Hoon, Choi Sung Hee, Jang Hak Chul, Park Kyong Soo, Lim Soo
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Diabetes Metab J. 2017 Feb;41(1):38-50. doi: 10.4093/dmj.2017.41.1.38. Epub 2016 Dec 16.
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the treatment of blood cholesterol recommends statin therapy for individuals at high risk of atherosclerotic cardiovascular disease (ASCVD). The aim of this study was to investigate serial trends in the percentages of Korean adults considered eligible for statin therapy according to the new ACC/AHA cholesterol guideline.
Data from the Korean National Health and Nutrition Examination Survey (KNHANES) I (1998, n=7,698), II (2001, n=5,654), III (2005, n=5,269), IV (2007 to 2009, n=15,727), and V (2010 to 2012, n=16,304), which used a stratified, multistage, probability sampling design, were used as representative of the entire Korean population.
The percentage of adults eligible for statin therapy according to the ACC/AHA cholesterol guideline increased with time: 17.0%, 19.0%, 20.8%, 20.2%, and 22.0% in KNHANES I, II, III, IV, and V, respectively (P=0.022). The prevalence of ASCVD was 1.4% in KNHANES I and increased to 3.3% in KNHANES V. The percentage of diabetic patients aged 40 to 75 years with a low density lipoprotein cholesterol levels of 70 to 189 mg/dL increased from 4.8% in KNHANES I to 6.1% in KNHANES V. People with an estimated 10-year ASCVD risk ≥7.5% and aged 40 to 75 years accounted for the largest percentage among the four statin benefit groups: 9.1% in KNHANES I and 11.0% in KNHANES V.
Application of the 2013 ACC/AHA guideline has found that the percentage of Korean adults in the statin benefit groups has increased over the past 15 years.
2013年美国心脏病学会/美国心脏协会(ACC/AHA)血液胆固醇治疗指南推荐对动脉粥样硬化性心血管疾病(ASCVD)高危个体使用他汀类药物治疗。本研究旨在调查根据新的ACC/AHA胆固醇指南,符合他汀类药物治疗条件的韩国成年人百分比的连续变化趋势。
韩国国家健康与营养检查调查(KNHANES)I(1998年,n = 7698)、II(2001年,n = 5654)、III(2005年,n = 5269)、IV(2007至2009年,n = 15727)和V(2010至2012年,n = 16304)的数据采用分层、多阶段概率抽样设计,作为全体韩国人口的代表。
根据ACC/AHA胆固醇指南,符合他汀类药物治疗条件的成年人百分比随时间增加:KNHANES I、II、III、IV和V中分别为17.0%、19.0%、20.8%、20.2%和22.0%(P = 0.022)。KNHANES I中ASCVD患病率为1.4%,在KNHANES V中增至3.3%。40至75岁低密度脂蛋白胆固醇水平为70至189 mg/dL的糖尿病患者百分比从KNHANES I中的4.